ArticleAdvances in therapy2025
Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: A Discrete Choice Experiment Among Patients in Five Non-Western Countries.
Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Severity or Incidence: Labeling Side-Effect Attributes in Discrete Choice Experiments.The patient · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionUnderstanding patient preferences is important for facilitating informed decision-making in managing patients with inflammatory bowel disease (IBD). This study explored the preferences of patients with Crohn's disease (CD) and ulcerative colitis (UC) regarding advanced therapy treatment attributes in five non-Western countries: Argentina, Australia, Brazil, Saudi Arabia and Taiwan.
methodsAdult patients with self-reported CD or UC treated for ≥ 6 months participated in this cross-sectional online survey. A discrete choice experiment assessed the relative importance of treatment attributes using conditional logit models. The primary objective was to estimate partworth utilities across the five countries (overall population).
resultsOverall, 706 patients with CD and UC (n = 353 each) completed the survey (mean age 36.8 and 37.7 years; female 47.9% and 47.6%; mean disease duration 4.5 and 4.6 years, respectively). For patients with CD, the rate of long-term remission on maintenance therapy (LTREM) was the most preferred treatment attribute (32.5%), followed by the rate of 1-year remission (25.7%), routes of administration (RoAs; 24.6%) and risk of serious adverse events (AEs) (11.5%) and mild AEs (5.8%). For patients with UC, the rate of corticosteroid-free remission after 1 year was the most important attribute (30.8%), followed by RoAs (27.4%), rate of mucosal healing after 1 year (16.1%), LTREM (14.9%) and risk of serious AEs (10.0%) and mild AEs (0.8%). Patients in both groups considered abdominal pain as the symptom most impacting their quality of life. Approximately half of the patients (CD 49.3%; UC 50.5%) exposed to advanced therapy indicated that they would have preferred to start advanced therapy earlier.
conclusionPatients with IBD from non-Western countries prioritised advanced treatment attributes such as efficacy outcomes and RoAs, although treatment preferences varied between patients with CD and UC. Shared decision-making between patients and physicians regarding advanced therapy choice and timing should occur throughout the treatment journey.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.